Anglo American, Milliken & Company, MOL Group, Koch Industries, Goldcorp and AccorHotels among the Excellence Award winners at Enablon's Sustainable Performance Forum
Enablon recognizes companies for effectively leveraging technology to improve their sustainability performance
CHICAGO, June 20, 2018 (GLOBE NEWSWIRE) -- Enablon, a Wolters Kluwer business and the world's leading provider of EHS, Operational Risk Management and Sustainability Software, announced today the winners of the 2018 Enablon Excellence Awards. The awards were given during a gala dinner at the Sustainable Performance Forum (SPF) in Chicago, and in Paris.
The Enablon Excellence Awards recognize organizations that are leading the way within their industry and that effectively leverage technology to improve their sustainability performance to benefit their business, and also their employees, customers and the communities in which they operate.
The 2018 Excellence Awards winners are:
- Enablon Excellence Award in EHS Performance: Koch Industries (Americas) & MOL Group (EMEA)
- Enablon Excellence Award in Governance, Risk & Compliance (EMEA): AccorHotels
- Enablon Excellence Award in Integrated Risk Management (Americas): Goldcorp
- Enablon Excellence Award in Technology Innovation: Colonial Pipeline
- Enablon Positive Impact Award: Anglo American (EMEA), Milliken & Company (Americas)
- Partner of the Year: Arcadis (Americas) & Laragon (EMEA)
- Technology Partner of the Year: TapRooT
"Every year, the SPF conferences are the place where forward-thinking professionals in EHS, Risk Management and Sustainability come together to discuss industry challenges and discover the newest innovations and technologies that allow them to add business value to their operations," said Chris Joseph, CEO of Enablon. The Enablon Excellence Awards give us the opportunity to celebrate some of the participants in that unique community. We are honored to recognize their accomplishments and to support them achieving their performance goals."
About Wolters Kluwer
Wolters Kluwer N.V. (AEX:WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services. Wolters Kluwer reported 2017 annual revenues of €4.4 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries, and employs 19,000 people worldwide. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
Enablon, a Wolters Kluwer business, is the world's leading provider of EH&S, Operational Risk Management and Sustainability Software. More than 1,000 global companies and 1 million users rely on Enablon software solutions to manage their environmental and social performance, minimize risks and improve profitability. Enablon offers the most comprehensive platform in the industry, and is consistently recognized as a global leader and visionary. For more information about Enablon: www.enablon.com.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enablon via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Data Privacy and Governance Solution Now Cloud-based18.6.2019 18:34:00 CEST | Pressemelding
HIPAAT Privacy eSuite adds support for Consent as a Service, enabling consumers to have direct control over their personal information NAPLES, FL and TORONTO, ON, June 18, 2019 (GLOBE NEWSWIRE) -- HIPAAT Inc. (HIPAAT), a leading provider of consent management, privacy-based access control and auditing solutions, today announced the release of version 6.0 of its consent engine, Privacy eSuite (PeS). The new version supports consumers’ ability to have direct control over their personal information privacy preferences. Those preferences may be recorded and managed, and – most importantly – consulted prior to their information being collected, used or disclosed. V6.0 improvements include support for HL7 Fast Health Interoperability Resources (FHIR) R4 for managing privacy policies and consent directives, RESTful interfaces for consent decisions and override requests, OAuth 2.0 protection for APIs as resources, and Open ID Connect and OAuth 2.0 for authenticating users and providing user pe
Boom Supersonic Partners with Prometheus Fuels to Supply Carbon Neutral Fuel for XB-1, its Mach-2.2 Demonstrator Aircraft18.6.2019 17:00:00 CEST | Pressemelding
Prometheus Fuels extracts CO2 from the air, creating hydrocarbon fuel with zero impact on greenhouse gas levels DENVER, June 18, 2019 (GLOBE NEWSWIRE) -- Boom Supersonic, the Colorado company building history’s fastest supersonic airliner, today announced a unique partnership with Prometheus Fuels. Prometheus will supply fuel during the flight test program of XB-1, Boom’s Mach-2.2 demonstrator aircraft. Boom plans to use Prometheus fuel to power XB-1 in the world’s first supersonic flight using carbon-neutral fuel. Through a process called direct air carbon capture, Prometheus removes carbon dioxide (CO2) from the air and uses clean electricity to transform it into gasoline, diesel, and jet fuel. The electricity used in this process comes from renewable sources such as solar and wind, so there are no net carbon emissions from using the fuel. “Boom is committed to making supersonic travel environmentally sustainable—we want society to enjoy the benefits of faster flight for generations
Parallels® Remote Application Server 17 Brings Simplicity and Scalability to End User Computing for Microsoft RDS, VDI and DaaS with Time-Saving Innovations18.6.2019 15:01:00 CEST | Pressemelding
BELLEVUE, Wash., June 18, 2019 (GLOBE NEWSWIRE) -- Today Parallels released version 17 of Parallels® Remote Application Server (Parallels RAS, parallels.com/ras) which simplifies end user computing for service providers (SPs) and enterprises. Parallels RAS 17 enables faster launch of applications by using artificial intelligence (AI), provides additional security features such as integration with Google Authenticator, and debuts a web-based helpdesk console to more easily manage Microsoft Remote Desktop Services (RDS), virtual desktop infrastructure (VDI) and desktop as a service (DaaS) infrastructure. Parallels RAS 17 is an all-in-one solution that empowers end users to consume business applications faster, reliably, and with the ability to scale within a single cloud or multiple clouds. SPs and enterprises can benefit from the Parallels RAS investment in improved management and deployment components. These provide new methods to control DaaS, VDI and Microsoft RDS, such as a new REST
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease18.6.2019 14:29:00 CEST | Pressemelding
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program. ABO-202, the Company’s novel one-time AAV9 gene therapy for CLN1 disease, is designed to deliver a functional copy of the PPT1 gene to the central nervous system and peripheral organs using a combination of intravenous and intrathecal administrations. Abeona is preparing to initiate a Phase 1/2 clinical trial evaluating ABO-202 in patients with CLN1 disease and will provide guidance on the timing of the trial later this year. “Receiving Fast Track designation acknowledges the urgency for developing a therapy for children suffering from this rapidly-progressing and fatal disease and highlights the significant potential of ABO-202 to address this unmet need,” said João Siffert, M.D., Chief Executive Officer. ABO-202 i
Nasdaq Launches Center for Corporate Governance18.6.2019 14:00:00 CEST | Pressemelding
New Informational Hub to Advance Global Insights and Research on Corporate Governance and Sustainability Practices for Public, Private, and Nonprofit Organizations Publishes Inaugural Research Report on Board and Investor Priorities of S&P 100 Companies NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today announced the founding of the Nasdaq Center for Corporate Governance (the “Governance Center”), a global information and research hub that will integrate Nasdaq’s expertise, insights, and technology to accelerate the understanding of emerging corporate governance and sustainable business practices. The ambition of the Governance Center is to support the work of boards, senior executives, and governance professionals at public, private, and nonprofit organizations. “Our mission with the Governance Center is to create a resource for corporate leaders, investors, and stakeholders that includes the latest governance insights and actionable intelligence, thereby su
Inspirata Unveils Comprehensive Insight Solutions for the Cancer Care Continuum18.6.2019 13:00:00 CEST | Pressemelding
Leading digital pathology company now offers technology-enabled insight solutions Tampa, Florida, June 18, 2019 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology solution provider Inspirata today unveiled its new end-to-end capabilities for the cancer care continuum. Founded as a digital pathology company that pioneered the use of digital imaging for accurate cancer diagnoses, Inspirata now offers cancer registry abstraction and insight solutions to drive better cancer diagnosis, treatment, performance, and research. Inspirata’s comprehensive solutions reveal a clear picture of patients, allowing clinicians to make every moment matter in delivering cancer care. With an existing global footprint that serves over 100 institutions with automated cancer identification and reporting, and more than 30 hospitals and laboratories with digital pathology, Inspirata processes over 20 million patient reports per year, identifying all reports containing reportable cancer. Today, the comp